SCHEMBL19575552

SCHEMBL19575552

OC[C@H]1CC[C@@H](n2cnc3c(Cl)nc(Cl)nc32)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.55
TP53 P04637 3/20 0.55
ADORA3 P0DMS8 2/20 0.43
ADORA2A P29274 2/20 0.43
ADORA1 P30542 2/20 0.43
PNP P00491 1/20 0.43
HTT P42858 1/20 0.43
PDE4D Q08499 1/20 0.43
PDE3A Q14432 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
CHKA P35790 8/20 0.43
ADORA2B P29275 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19553671 1.00 LMNA (0.55) LMNATP53ADORA3ADORA2AADORA1
SCHEMBL27087643 0.92 LMNA (0.53) LMNATP53ADORA3ADORA2AADORA1
SCHEMBL30332447 0.90 LMNA (0.50) LMNATP53ADORA3ADORA2AADORA1
SCHEMBL786767 0.90 LMNA (0.50) LMNATP53ADORA3ADORA2AADORA1
SCHEMBL19575553 0.88 PDE4D (0.57) LMNATP53ADORA3ADORA2AADORA1
SCHEMBL30332114 0.84 ADORA2A (0.49) LMNATP53ADORA3ADORA2AADORA1
SCHEMBL16714635 0.84 ADORA2A (0.49) LMNATP53ADORA3ADORA2AADORA1
SCHEMBL786455 0.84 ADORA2A (0.49) LMNATP53ADORA3ADORA2AADORA1
SCHEMBL30677364 0.83 LMNA (0.48) LMNATP53ADORA3ADORA2AADORA1
SCHEMBL30584024 0.82 ADORA2A (0.50) LMNATP53ADORA3ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3452477-B1 ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS B C I PHARMA (BE) 2023-09-13 EP disclosed
US-11236093-B2 Adenine derivatives as protein kinase inhibitors B.C.I. PHARMA (BE) 2022-02-01 US disclosed
US-20190127379-A1 ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS B.C.I. PHARMA (BE) 2019-05-02 US disclosed
WO-2017191297-A1 ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS BCI PHARMA (FR) 2017-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11236093-B2 Adenine derivatives as protein kinase inhibitors ADK, TNNI3K, TNK2 LMNA 873/4885TP53 1449/4885ADORA3 132/4885
US-20190127379-A1 ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS ADK, TNNI3K, TNK2 LMNA 873/4885TP53 1449/4885ADORA3 132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.